JANX Janux Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1817713 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY132.9%
TTM net income YoY2.0%
TTM EPS YoY4.8%
Revenue 3-yr CAGR40.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-599.3%
Net margin-428.7%
FCF margin-232.6%
EBITDA margin-591.3%
Returns
ROE-10.6%
ROA-9.9%
ROIC (approx.)-12.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets7.3%
Debt / equity0.00x
Current ratio17.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.00M | $10.59M |
| R&D expense | $125.90M | $68.39M |
| SG&A expense | $41.77M | $41.05M |
| Operating income | -$157.67M | -$98.85M |
| Income tax | $0 | $0 |
| Net income | -$113.62M | -$68.99M |
| EBITDA | -$155.64M | -$96.79M |
| EPS (basic) | -1.83 | -1.28 |
| EPS (diluted) | -1.83 | -1.28 |
| Weighted avg. shares (diluted) | 61.97M | 53.75M |
| Balance sheet | ||
| Cash & equivalents | $52.33M | $430.61M |
| Short-term investments | $914.23M | $594.57M |
| Receivables | $0 | — |
| Current assets | $975.89M | $1.03B |
| PP&E, net | $3.85M | $4.86M |
| Total assets | $1.00B | $1.06B |
| Current liabilities | $25.00M | $17.46M |
| Total liabilities | $44.74M | $38.73M |
| Shareholders' equity | $956.82M | $1.02B |
| Shares outstanding | 60.38M | 59.06M |
| Cash flow statement | ||
| Operating cash flow | -$82.23M | -$43.81M |
| Capital expenditure | $1.04M | $359,000 |
| Free cash flow | -$83.28M | -$44.17M |
| Investing cash flow | -$300.98M | -$258.02M |
| Financing cash flow | $4.95M | $713.24M |
| Depreciation & amortization | $2.03M | $2.06M |
| Stock-based compensation | $40.22M | $33.02M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.